Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

2.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Decraene C, Silveira AB, Bidard FC, Vallée A, Michel M, Melaabi S, Vincent-Salomon A, Saliou A, Houy A, Milder M, Lantz O, Ychou M, Denis MG, Pierga JY, Stern MH, Proudhon C.

Clin Chem. 2018 Feb;64(2):317-328. doi: 10.1373/clinchem.2017.272518. Epub 2017 Nov 9.

PMID:
29122835
3.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

PMID:
28884749
4.

Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.

Buecher B, De Pauw A, Bazire L, Houdayer C, Fievet A, Moncoutier V, Farkhondeh F, Melaabi S, Lyonnet DS, Golmard L.

Fam Cancer. 2018 Apr;17(2):281-285. doi: 10.1007/s10689-017-0032-8.

PMID:
28819700

Supplemental Content

Loading ...
Support Center